知搜-全球专利检索

  1. 登录
  2. 注册
发明公开
CN103816170A 由植生链霉菌产生的诺沃巢霉素在制备抗肿瘤制剂的应用 失效 - 权利终止

由植生链霉菌产生的诺沃巢霉素在制备抗肿瘤制剂的应用
摘要：
本发明涉及由植生链霉菌产生的诺沃巢霉素在制备抗肿瘤制剂的应用，植生链霉菌（Streptomyces？phytohabitans）菌种代号HBERC-20821，由植生链霉菌产生两种新抗生素，分别命名为诺沃巢霉素A(Novonestmycin？A)、诺沃巢霉素B(Novonestmycin？B)，诺沃巢霉素A、诺沃巢霉素B具有显著的抗肿瘤活性，体外抗肿瘤活性测定结果表明，对多种人肿瘤细胞系，如人肝肿瘤细胞系HepG2、Bel-7402，人胃癌细胞系BGC-823，人乳腺癌细胞系MCF-7具有强烈的抑制活性，对耐5-氟尿嘧啶肿瘤细胞Bel-7402有良好的抗肿瘤活性，可用作制备抗肿瘤制剂。
摘要（英）：

The invention relates to the application of novonestmycin generated by streptomyces phytohabitans in the preparation of antitumor agents. Streptomyces phytohabitans of which the number is HBERC-20821 is used to generate two kinds of antibiotics which are respectively named novonestmycin A and novonestmycin B. The novonestmycin A and novonestmycin B have significant antitumor activities, and the measurement result of antitumor activity in vitro indicates that novonestmycin A and novonestmycin B have strong inhibitory activity to various human tumor cell lines such as human liver tumor cell lines HepG2, Bel-7402, human stomach cancer cell line BGC-823, human breast cancer cell line MCF-7, and have good antitumor activity to tumor cells Bel-7402 resistant to 5-fluorouracil, so that novonestmycin can be used for preparing antitumor agents.

公开/授权文献
0/0